709 related articles for article (PubMed ID: 9440663)
1. The cost-effectiveness of preventing AIDS-related opportunistic infections.
Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
[TBL] [Abstract][Full Text] [Related]
2. Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis.
Bayoumi AM; Redelmeier DA
AIDS; 1998 Aug; 12(12):1503-12. PubMed ID: 9727572
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.
Goldie SJ; Kaplan JE; Losina E; Weinstein MC; Paltiel AD; Seage GR; Craven DE; Kimmel AD; Zhang H; Cohen CJ; Freedberg KA
Arch Intern Med; 2002 Apr; 162(8):921-8. PubMed ID: 11966344
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of prophylaxis for Mycobacterium avium complex in AIDS.
Scharfstein JA; Paltiel AD; Weinstein MC; Seage GR; Losina E; Craven DE; Freedberg KA
Int J Technol Assess Health Care; 1999; 15(3):531-47. PubMed ID: 10874380
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis.
Freedberg KA; Cohen CJ; Barber TW
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Aug; 15(4):275-82. PubMed ID: 9292586
[TBL] [Abstract][Full Text] [Related]
6. Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients.
Freedberg KA; Hardy WD; Holzman RS; Tosteson AN; Craven DE
Med Decis Making; 1996; 16(1):29-35. PubMed ID: 8717596
[TBL] [Abstract][Full Text] [Related]
7. Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis.
Yazdanpanah Y; Goldie SJ; Paltiel AD; Losina E; Coudeville L; Weinstein MC; Gerard Y; Kimmel AD; Zhang H; Salamon R; Mouton Y; Freedberg KA
Clin Infect Dis; 2003 Jan; 36(1):86-96. PubMed ID: 12491207
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis for opportunistic infections among HIV-infected patients receiving medical care.
Sackoff J; McFarland J; Su S; Bryan E
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):387-92. PubMed ID: 9833748
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis of opportunistic infections in adults and children with HIV infection.
AIDS Inst Newsl; 1995 Jun; ():1-12. PubMed ID: 11367408
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort Study.
Sendi PP; Craig BA; Meier G; Pfluger D; Gafni A; Opravil M; Battegay M; Bucher HC
J Antimicrob Chemother; 1999 Dec; 44(6):811-7. PubMed ID: 10590283
[TBL] [Abstract][Full Text] [Related]
11. Preventing opportunistic infections.
Cheng B
PI Perspect; 1995 May; (no 16):14-5. PubMed ID: 11362422
[TBL] [Abstract][Full Text] [Related]
12. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.
Jones JL; Hanson DL; Dworkin MS; Alderton DL; Fleming PL; Kaplan JE; Ward J
MMWR CDC Surveill Summ; 1999 Apr; 48(2):1-22. PubMed ID: 12412613
[TBL] [Abstract][Full Text] [Related]
13. Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease.
Hoffmann T; Brunner H
Eur J Health Econ; 2004 Jun; 5(2):129-35. PubMed ID: 15452749
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis.
Moore RD; Chaisson RE
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Sep; 16(1):15-21. PubMed ID: 9377120
[TBL] [Abstract][Full Text] [Related]
15. State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards.
Johri M; David Paltiel A; Goldie SJ; Freedberg KA
Med Care; 2002 May; 40(5):429-41. PubMed ID: 11961477
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy.
Chung JB; Armstrong K; Schwartz JS; Albert D
Arthritis Rheum; 2000 Aug; 43(8):1841-8. PubMed ID: 10943875
[TBL] [Abstract][Full Text] [Related]
17. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection.
Paltiel AD; Scharfstein JA; Seage GR; Losina E; Goldie SJ; Weinstein MC; Craven DE; Freedberg KA
Med Decis Making; 1998; 18(2 Suppl):S93-105. PubMed ID: 9566470
[TBL] [Abstract][Full Text] [Related]
18. Analysis of life-long strategies to prevent Pneumocystis carinii pneumonia in patients with variable HIV progression rates.
Wynia MK; Ioannidis JP; Lau J
AIDS; 1998 Jul; 12(11):1317-25. PubMed ID: 9708411
[TBL] [Abstract][Full Text] [Related]
19. The cost effectiveness of combination antiretroviral therapy for HIV disease.
Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis.
Yazdanpanah Y; Losina E; Anglaret X; Goldie SJ; Walensky RP; Weinstein MC; Toure S; Smith HE; Kaplan JE; Freedberg KA;
AIDS; 2005 Aug; 19(12):1299-308. PubMed ID: 16052085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
